Solventum Corporation (SOLV) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Solventum Corporation (SOLV) Healthcare & Pipeline Overview

Solventum Corporation, a healthcare solutions provider, develops and commercializes medical and dental products across four segments including Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. With a $15.2B market cap and a 17.3% profit margin, Solventum addresses critical patient needs within the evolving healthcare landscape.

What Is the Investment Thesis for SOLV?

Solventum Corporation presents a notable research candidate within the healthcare sector, driven by its diverse portfolio of medical and dental solutions. With a market capitalization of $15.2B and a P/E ratio of 10.89, the company demonstrates solid financial metrics. A gross margin of 53.7% and a profit margin of 17.3% indicate efficient operations. Growth catalysts include expansion within its Medsurg and Dental Solutions segments, as well as potential advancements in its Health Information Systems. Potential risks include competitive pressures and regulatory changes within the healthcare industry. The company's beta of 0.77 suggests lower volatility compared to the broader market.

Based on FMP financials and quantitative analysis

SOLV Key Highlights

Market Cap of $15.2B indicates a strong market presence within the healthcare sector.

• P/E ratio of 10.89 suggests the company may be undervalued compared to its earnings.
• Profit Margin of 17.3% demonstrates efficient profitability in its operations.
• Gross Margin of 53.7% indicates a strong ability to manage production costs.
• Beta of 0.77 suggests lower volatility compared to the overall market, potentially offering a more stable investment.

Who Are SOLV's Competitors?

SOLV is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are SOLV's Key Strengths?

Diverse product portfolio across multiple healthcare segments.

• Strong brand reputation and established customer relationships.
• Proprietary technologies and intellectual property.
• Efficient operations with a profit margin of 17.3%.

What Are SOLV's Weaknesses?

Dependence on specific product lines for revenue.

• Potential for product recalls or safety concerns.
• Exposure to regulatory changes in the healthcare industry.
• Limited presence in emerging markets compared to larger competitors.

What Could Drive SOLV Stock Higher?

SOLV catalyst: Launch of new advanced wound care products in Q3 2026, expected to drive revenue growth in the Medsurg segment.

• Expansion of the Dental Solutions segment into emerging markets, particularly in Asia-Pacific, to capture new growth opportunities.
• Continued investment in R&D to develop innovative health information systems solutions, enhancing the company's competitive advantage.
• Potential acquisitions of complementary businesses to expand the product portfolio and enter new markets by the end of 2026.

What Are the Key Risks for SOLV?

Insider selling — insiders were net sellers of roughly $4.4M recently.

• Intense competition from established healthcare companies, which could lead to pricing pressures and reduced market share.
• Regulatory changes in the healthcare industry, which could impact the company's operations and profitability.
• Patent expirations and generic competition, which could erode revenue from key products.
• Economic downturns affecting healthcare spending, which could reduce demand for the company's products and services.
• Product recalls or safety concerns, which could damage the company's reputation and lead to financial losses.

What Are the Growth Opportunities for SOLV?

• Growth opportunity 1: Expansion in Advanced Wound Care: Solventum can capitalize on the growing market for advanced wound care products, driven by an aging population and increasing prevalence of chronic diseases such as diabetes. The global advanced wound care market is projected to reach $22 billion by 2027. Solventum's Medsurg segment is well-positioned to capture a larger share of this market through innovative product development and strategic partnerships. This expansion can be achieved through increased R&D spending and targeted marketing efforts.
• Growth opportunity 2: Penetration of the Dental Solutions Market: The global dental solutions market is experiencing steady growth, driven by increasing awareness of oral hygiene and advancements in dental technology. Solventum's Dental Solutions segment can expand its market share by introducing new and improved dental and orthodontic products, particularly in emerging markets.
• Growth opportunity 3: Innovation in Health Information Systems: The demand for advanced health information systems is increasing as healthcare providers seek to improve efficiency, reduce costs, and enhance patient care. Solventum's Health Information Systems segment can drive growth by developing innovative software solutions that leverage artificial intelligence, machine learning, and data analytics. The global healthcare IT market is projected to reach $390 billion by 2027, presenting a substantial growth opportunity for Solventum.
• Growth opportunity 4: Expansion in Purification and Filtration Technologies: The global market for purification and filtration technologies is growing, driven by increasing demand for clean water and air, as well as stringent environmental regulations. Solventum's Purification and Filtration segment can expand its market presence by developing and commercializing advanced filtration solutions for various applications, including healthcare, industrial, and residential. The global filtration market is expected to reach $100 billion by 2026.
• Growth opportunity 5: Strategic Acquisitions and Partnerships: Solventum can pursue strategic acquisitions and partnerships to expand its product portfolio, enter new markets, and enhance its technological capabilities. By acquiring complementary businesses and forming alliances with other healthcare companies, Solventum can accelerate its growth and strengthen its competitive position. This strategy can be particularly effective in expanding its presence in high-growth areas such as digital health and personalized medicine. The timeline for realizing these benefits will depend on the specific acquisitions and partnerships pursued.

What Are SOLV's Competitive Advantages?

• Diversified product portfolio across multiple healthcare segments.
• Established brand reputation and customer relationships.
• Proprietary technologies and intellectual property.
• Strong distribution network and global reach.

What Does SOLV Do?

Solventum Corporation, incorporated in 2023 and based in Saint Paul, Minnesota, is a healthcare company focused on developing, manufacturing, and commercializing a diverse portfolio of healthcare solutions. The company operates through four key segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment offers solutions such as advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes. The Dental Solutions segment provides a comprehensive suite of dental and orthodontic products, including brackets, aligners, restorative cements, and bonding agents. The Health Information Systems segment delivers software solutions, including computer-assisted physician documentation, direct-to-bill and coding automation, classification methodologies, speech recognition, and data visualization platforms. The Purification and Filtration segment offers purification and filtration technologies, including filters, purifiers, cartridges, and membranes. Solventum's products are designed to address critical customer and patient needs across the healthcare spectrum, positioning it as a key player in the medical and dental solutions market.

What Products and Services Does SOLV Offer?

• Develops and manufactures medical and dental solutions.
• Offers advanced wound care products and I.V. site management solutions.
• Provides dental and orthodontic products including brackets and aligners.
• Delivers health information systems software for physician documentation and coding automation.
• Offers purification and filtration technologies for various applications.
• Commercializes its products to address critical customer and patient needs in healthcare.

How Does SOLV Make Money?

• Develops and manufactures a range of healthcare products and solutions.
• Sells its products through direct sales, distributors, and partnerships.
• Generates revenue from the sale of medical and dental products, software solutions, and filtration technologies.
• Invests in research and development to innovate and expand its product portfolio.

What Industry Does SOLV Operate In?

Solventum Corporation operates within the healthcare industry, specifically in the medical and dental solutions market. The industry is characterized by continuous innovation, increasing demand for advanced medical technologies, and evolving regulatory landscapes. The competitive landscape includes companies such as ALGN: Align Technology, Inc. and RDY: Dr. Reddy's Laboratories Limited. Solventum's diversified portfolio across Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration positions it to capitalize on various growth opportunities within the broader healthcare market. The global medical devices market is projected to reach $600 billion by 2028, reflecting substantial growth potential.

Who Are SOLV's Key Customers?

• Hospitals and healthcare providers
• Dental clinics and orthodontists
• Healthcare IT departments
• Industrial and commercial businesses requiring filtration solutions

Company Profile

Solventum Corporation operates in the Medical - Instruments & Supplies industry within the Healthcare sector. It is headquartered in Eagan, US. The company is led by CEO Bryan C. Hanson. SOLV has traded publicly since 2024.

Solventum Corporation Financial Trajectory

Solventum Corporation (SOLV) reported $2.21B in revenue for Q2 FY2026, reflecting 10.1% growth compared to the prior quarter. The company recorded net income of $92.0M, with diluted EPS of $0.53. Revenue has increased across the last three reported quarters, suggesting sustained momentum for this large-cap Healthcare company. Across the four most recent quarters, SOLV averaged $2.04 in diluted EPS.

How Solventum Corporation Is Valued

Solventum Corporation carries a market capitalization of $15.2B, placing it in the large-cap category. Analyst price targets span from $43.00 to $113.00, with a consensus of $91.22. At the current price of $87.80, that implies approximately 4% upside potential. Relative to its peer group, SOLV's quantitative score of 59/100 is below the peer average of 75/100.

Return on equity for Solventum Corporation stands at 29.0%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 10.1%, showing how much profit it generates from its asset base. SOLV trades at a trailing price-to-earnings ratio of 10.89, below the Healthcare sector average of ~21.50x. Its free cash flow yield is -0.8%, a gauge of the cash the business throws off relative to its market value. A current ratio of 1.02 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 9.2%, the inverse of the P/E and a quick read on earnings relative to price.

Solventum Corporation's Piotroski F-Score is 7/9, a 9-point checklist of profitability, leverage and efficiency — signaling solid underlying fundamentals. Its Altman Z-Score of 2.20 places it in the grey zone, a middle ground that warrants monitoring.

Solventum Corporation has beaten Wall Street's EPS estimate in 8 of its last 8 reported quarters — a consistent record of delivering on expectations. Reported results have landed about 13.3% above estimates on average.

Over the past six months, Solventum Corporation insiders filed 83 SEC Form 4 transactions — 40 sales and 43 purchases. On net that is roughly 9K shares disposed (about $4.4M), a signal worth weighing alongside the fundamentals.

SOLV Financials

SOLV earnings history & estimates →

SOLV Latest News

SOLV Analyst Consensus

SOLV MoonshotScore

Latest Solventum Corporation Analysis

Common Questions About SOLV (Healthcare)

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources